Indigo offers a generalist care offer in response to the increasing demand for care and the changing playing field. Generalist care is offered by Indigo in or near the GP practice, is accessible, does not unnecessarily medicalise and is immediately accessible without waiting times. This care meets the needs of a large group of clients, who are now receiving specialist mental health care in the second line.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ALX RAISES $105M FOR MIDPHASE TRIALS OF CD47 CANCER DRUG

FierceBiotech | February 12, 2020

news image

ALX Oncology has raised $105 million. The series C round will support phase 2 trials of CD47 myeloid checkpoint inhibitor ALX148 in combination with other anti-cancer therapies. Multiple drug developers have gone after CD47 since evidence of its role in the interactions between cancer cells and the immune system became clear. The evidence suggested tumors evade immune attacks by upregulating CD47, leading researchers to posit that blocking the signal will expose cancer cells to a full-force offe...

Read More

Cell and Gene Therapy

WUXI ATU ANNOUNCES LAUNCH OF TESSA™ TECHNOLOGY TO IMPROVE SCALABILITY AND ACCESSIBILITY OF CELL AND GENE THERAPIES

WuXi AppTec | March 08, 2022

news image

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™). This technology is a state-of-the-art novel process for transfection-free, scalable manufacture of adeno-associated virus (AAV) at Good Manufacturing Practice (GMP) grade. Developed by OXGENE in the United Kingdom, a WuXi Advanced Therapies company, TESSA™ will expedite AAV manufacturing and significantly reduce the cost ...

Read More

Medical

TGEN SELECTS MEMVERGE TO ACCELERATE IDIOPATHIC PULMONARY FIBROSIS RESEARCH DISCOVERY WITH BIG MEMORY TECHNOLOGY

MemVerge | March 21, 2022

news image

MemVerge™, the pioneers of Big Memory software, today announced that TGen, the Translational Genomics Research Institute, an affiliate of City of Hope, has selected MemVerge Memory Machine Big Memory virtualization software to accelerate time to discovery for Idiopathic Pulmonary Fibrosis (IPF), a disease which affects 100,000 people annually in the U.S. Using MemVerge technology, TGen is able to dramatically speed analytical processing by nearly 36% for single-cell RNA sequencing. ...

Read More

AI

DEARGEN ANNOUNCES NEW MODEL FOR OPTIMIZING DRUG CANDIDATE MOLECULES WITH NEARLY DOUBLED PERFORMANCE COMPARED TO EXISTING MODELS

Deargen | April 12, 2021

news image

Deargen, a drug research and development biotech company based on artificial intelligence (AI), announced on April 9 that it presented study results on controlled molecule generator (CMG) technology at the ACM Conference on Health, Inference, and Learning (ACM CHIL) 2021. CMG technology can modify many properties of molecules at the same time. The Association for Computing Machinery (ACM), based in New York, is one of the world's most prominent academic organizations. The ACM ...

Read More
news image

ALX RAISES $105M FOR MIDPHASE TRIALS OF CD47 CANCER DRUG

FierceBiotech | February 12, 2020

ALX Oncology has raised $105 million. The series C round will support phase 2 trials of CD47 myeloid checkpoint inhibitor ALX148 in combination with other anti-cancer therapies. Multiple drug developers have gone after CD47 since evidence of its role in the interactions between cancer cells and the immune system became clear. The evidence suggested tumors evade immune attacks by upregulating CD47, leading researchers to posit that blocking the signal will expose cancer cells to a full-force offe...

Read More
news image

Cell and Gene Therapy

WUXI ATU ANNOUNCES LAUNCH OF TESSA™ TECHNOLOGY TO IMPROVE SCALABILITY AND ACCESSIBILITY OF CELL AND GENE THERAPIES

WuXi AppTec | March 08, 2022

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™). This technology is a state-of-the-art novel process for transfection-free, scalable manufacture of adeno-associated virus (AAV) at Good Manufacturing Practice (GMP) grade. Developed by OXGENE in the United Kingdom, a WuXi Advanced Therapies company, TESSA™ will expedite AAV manufacturing and significantly reduce the cost ...

Read More
news image

Medical

TGEN SELECTS MEMVERGE TO ACCELERATE IDIOPATHIC PULMONARY FIBROSIS RESEARCH DISCOVERY WITH BIG MEMORY TECHNOLOGY

MemVerge | March 21, 2022

MemVerge™, the pioneers of Big Memory software, today announced that TGen, the Translational Genomics Research Institute, an affiliate of City of Hope, has selected MemVerge Memory Machine Big Memory virtualization software to accelerate time to discovery for Idiopathic Pulmonary Fibrosis (IPF), a disease which affects 100,000 people annually in the U.S. Using MemVerge technology, TGen is able to dramatically speed analytical processing by nearly 36% for single-cell RNA sequencing. ...

Read More
news image

AI

DEARGEN ANNOUNCES NEW MODEL FOR OPTIMIZING DRUG CANDIDATE MOLECULES WITH NEARLY DOUBLED PERFORMANCE COMPARED TO EXISTING MODELS

Deargen | April 12, 2021

Deargen, a drug research and development biotech company based on artificial intelligence (AI), announced on April 9 that it presented study results on controlled molecule generator (CMG) technology at the ACM Conference on Health, Inference, and Learning (ACM CHIL) 2021. CMG technology can modify many properties of molecules at the same time. The Association for Computing Machinery (ACM), based in New York, is one of the world's most prominent academic organizations. The ACM ...

Read More

Resources

resource image

Cell and Gene Therapy, Industrial Impact

Single-cell RNA Sequencing and Analysis

Video

resource image

MedTech, Industrial Impact

Asia Pacific – Clinical trial landscape

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

Using Clinical Breakpoints to Improve Antimicrobial Resistance Detection

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

Single-cell RNA Sequencing and Analysis

Video

resource image

MedTech, Industrial Impact

Asia Pacific – Clinical trial landscape

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

Using Clinical Breakpoints to Improve Antimicrobial Resistance Detection

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us